<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza is an acute respiratory and highly infectious disease that is mainly caused by influenza A viruses (IAVs), posing a serious public health problem globally. According to the World Health Organization (WHO), influenza epidemics are estimated to result in about three to five million cases of severe illness and up to 650,000 respiratory deaths annually [
 <xref rid="B1-viruses-11-00826" ref-type="bibr">1</xref>]. Further, the increase of zoonotic transmission with avian influenza viruses is a growing concern [
 <xref rid="B2-viruses-11-00826" ref-type="bibr">2</xref>,
 <xref rid="B3-viruses-11-00826" ref-type="bibr">3</xref>]. Two classes of anti-influenza drugs are currently available in most countries, including viral ion channel M2 blockers (amantadine and rimantadine) and neuraminidase inhibitors (NAIs; oseltamivir, zanamivir, peramivir, and laninamivir) [
 <xref rid="B4-viruses-11-00826" ref-type="bibr">4</xref>,
 <xref rid="B5-viruses-11-00826" ref-type="bibr">5</xref>]. However, M2 inhibitors are not recommended for clinical use due to widespread resistance, and there is also a concern for NAIs since global circulation of the oseltamivir-resistant seasonal A(H1N1) virus occurred in 2008â€“2009 [
 <xref rid="B6-viruses-11-00826" ref-type="bibr">6</xref>,
 <xref rid="B7-viruses-11-00826" ref-type="bibr">7</xref>,
 <xref rid="B8-viruses-11-00826" ref-type="bibr">8</xref>]. Numerous drugs with alternate modes of action are in development, including those targeting viral hemagglutinin and RNA-dependent RNA polymerase (RdRp), as well as host components (reviewed in [
 <xref rid="B9-viruses-11-00826" ref-type="bibr">9</xref>,
 <xref rid="B10-viruses-11-00826" ref-type="bibr">10</xref>]).
</p>
